Event
17th Annual Paragraph IV Disputes Conference
April 26-27, 2022
David Abramowitz and Carolyn Blessing will speak at ACI’s 17th Annual Paragraph IV Disputes Conference on April 26 -27, 2022. Locke Lord is a sponsor.
Carolyn's panel is “The Practice of PIV Disputes Advanced Pleadings Drafting: Choosing Claims and Defenses Wisely” on April 26. David is a panelist on “Brand and Generic Perspectives on the Latest FDA Initiatives Impacting Pharmaceutical Patents” on April 27.
The ACI’s Paragraph IV Disputes Conference hosts the community of Hatch-Waxman practitioners and is part of the only event which shapes the law, policy, and proceedings of Paragraph IV litigation. This in-person event will allow the participants to benchmark, network, and connect with peers (and opponents) while getting caught up on the latest legal developments, and the shifting legislative and regulatory landscape.
For additional details, click here.
Carolyn's panel is “The Practice of PIV Disputes Advanced Pleadings Drafting: Choosing Claims and Defenses Wisely” on April 26. David is a panelist on “Brand and Generic Perspectives on the Latest FDA Initiatives Impacting Pharmaceutical Patents” on April 27.
The ACI’s Paragraph IV Disputes Conference hosts the community of Hatch-Waxman practitioners and is part of the only event which shapes the law, policy, and proceedings of Paragraph IV litigation. This in-person event will allow the participants to benchmark, network, and connect with peers (and opponents) while getting caught up on the latest legal developments, and the shifting legislative and regulatory landscape.
For additional details, click here.
Don't miss a beat.
Sign up for our newsletter and get the latest to your inbox.
RELATED PROFESSIONALS
Disclaimer
Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.